← Back to Patent Explorer
US4743693A Expired / Lapsed US ⏱️ 0.0 years remaining

Process for the preparation of a stable modification of torasemide

Assignee: Roche Diagnostics GmbH
•
Filing: 1986-08-11
•
Granted: 1988-05-10
•
Expires: 2006-08-11
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention provides a process for the preparation of crystalline torasemide in the pure modification I (monoclinic, space group P21/c, melting point 162 DEG C.) from torasemide of modification II (monoclinic, space group P2/n, melting point 169 DEG C.), wherein a suspension of torasemide of modification II is stirred in water with the addition of a catalytic amount of modification I until the rearrangement is complete. The present invention also provides a pharmaceutical compositions containing torasemide of modification I.

Inventors

  • 👤 Fritz Topfmeier
  • 👤 Gustav Lettenbauer

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-09 18:41
CPC Classifications
C; C07; C07D; C07D213/00; C07D213/02; C07D213/04; C07D213/60; C07D213/72; C07D213/74; A; A61; A61P; A61P7/00; A61P7/10

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 67 words
A process for the preparation of torasemide in the pure modification I (monoclinic, space group P2 1 /c, metling point 162° C.) from torasemide of modification II (monoclinic, space group P2/n, melting point 169° C.), comprising stirring a suspension of torasemide of modification II in water with at least a catalytic amount of modification I, to rearrange the torasemide in modification II into torasemide of modification I.
Claim 2
Dependent Claim 67 words
A process for the preparation of torasemide in the pure modification I (monoclinic, space group P2 1 /c, metling point 162° C.) from torasemide of modification II (monoclinic, space group P2/n, melting point 169° C.), comprising stirring a suspension of torasemide of modification II in water with at least a catalytic amount of modification I, to rearrange the torasemide in modification II into torasemide of modification I.
Claim 3
Dependent Claim 37 words
The process of claim 1, wherein the rearrangement is carried out at a temperature of from ambient temperature to 90° C. and the rearrangement is carried out for a time of from 3 hours to 14 days.
Claim 4
Dependent Claim 31 words
The process of claim 2, wherein the torasemide of modification II is used in the form of a salt-containing, approximately neutral solution, obtained by the precipitation of torasemide from alkaline solution.
Claim 5
Dependent Claim 18 words
The process of claim 2, wherein crystalline torasemide of modification I is recovered from the rearrangement reaction mixture.
Claim 6
Dependent Claim 18 words
The process of claim 1, wherein crystalline torasemide of modification I is recovered from the rearrangement reaction mixture.
Claim 7
Dependent Claim 31 words
The process of claim 1, wherein the torasemide of modification II is used in the form of a salt-containing, approximately neutral solution, obtained by the precipitation of torasemide from alkaline solution.

References Cited (Backward Citations)

DE2516025A1 Cited
US4018929A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1991-05-10 1991-11-09 1992-05-10 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1995-05-10 1995-11-09 1996-05-10 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1999-05-10 1999-11-09 2000-05-10 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag